Garsorasib
- Generic Name
- Garsorasib
- Brand Names
- 安方宁
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT06435455
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 522
- Registration Number
- NCT06300177
- Locations
- 🇨🇳
Weihai Municipal Hospital, Weihai, Shandong, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Anhui Province Hospital, Hefei, Anhui, China
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT06233916
- Locations
- 🇨🇳
beijing Gobroad Boren Hospital, Beijing, China
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06166836
- Locations
- 🇨🇳
General Hospital Of Eastern Theater Command, Nanjing, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, China
🇨🇳Hunan Cancer Hospital, Changsha, China
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT06105255
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT05492045
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Study to Evaluate D-1553 in Subjects With Lung Cancer
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 225
- Registration Number
- NCT05383898
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 92
- Registration Number
- NCT05379946
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China
Study to Evaluate D-1553 in Subjects With Solid Tumors
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT04585035
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.